Further research found that the SRSF2P95H mutation in leukemia inhibits SRSF2 recognition of m5C, affecting mRNA alternative splicing mediated by SRSF2, and leukemia patients with impaired SRSF2‐m5C binding have poor prognosis.280. Here, SRSF2 is linked to leukemia.